Goldman Sachs ratings triggered price movements, with Syngene and Neuland rising but Laurus falling. Syngene is set to benefit from China+1, while Neuland sees growth opportunities in APIs and chemistry solutions. In contrast, Laurus faces challenges in its business transition and growth prospects.
Deepak Shenoy discusses excitement for auto stocks and auto ancillaries, potential investments in M&M and cautious optimism on two-wheeler sales. he also suggests monitoring of FDA actions in the pharma sector. Shenoy says a quantitatively driven, price driven strategy will make them consider pharma again,He also anticipates growth in the healthcare sector and potential opportunities in the chemical space.
Vishal Malkan expects midcaps and smallcaps to consolidate in April. Nifty to remain range-bound. Dr Lal PathLabs surges, correction awaited for entry. Weakness in Nifty IT index continues. Malkan says: "I like the main part of PSUs like the PSU banks which are my favourites. Canara Bank and PNB are my top two stocks for this year."
In the last three years, Novartis is the third MNC pharma company which has announced sale of a part of its business in India. Some of these restructuring are being done as part of the global readjustment being made at the parent companies level. The bigger question is whether after this restructuring will the MNC pharma stocks, which have been underperforming for quite some time, be able to make a comeback on the street or not. This answer to this question would depend on multiple factors. Right from the use of the sale proceeds to whether post restructuring focus would be on a 100 percent subsidiary or not. In both positive and negative cases, these stocks probably should be on watchlist as news flow around them increases in coming quarters. We take a look at 7 MNC pharma companies.
The pharma stock rose from Rs 291 on August 14 to Rs 435 recorded on February 15, which translates into an upside of about 50% in six months. It rose more than 6% in a week and over 20% in the last 3 months. The momentum helped the stock to break out from a month-long consolidation.